Pharmacology of antidepressants

Mayo Clinic Proceedings

Volumn 76, Issue 5, 2001, Pages 511-527

  Richelson, Elliott ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; MIRTAZAPINE; REBOXETINE;

BRADYCARDIA; DEPRESSION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; GASTROINTESTINAL SYMPTOM; HUMAN; PREVALENCE; REVIEW; SEROTONINERGIC NERVE CELL; SINUS TACHYCARDIA; SYNAPTIC TRANSMISSION; TREMOR; XEROSTOMIA;

EID: 0035025833     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/76.5.511     Document Type: Review

References (170)

1. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto US mental and addictive disorders service system: epidemiologic catchment area prospective 1 -year prevalence rates of disorders and services. Arch Gen Psychiatry. 1993;50:85-94.
2. Fichter MM, Narrow WE, Roper MT, et al. Prevalence of mental illness in Germany and the United States: comparison of the Upper Bavarian Study and the Epidemiologic Catchment Area Program. J Nerv Ment Dis. 1996; 184:598-606.
3. Hirschfeld RM, Keller MB, Panico S, et al. The National Depressive and Manie-Depressive Association consensus statement on the undertreatment of depression. JAMA. 1997;277:333-340.
4. Kühn R. The treatment of depressive states with G 22355 (imipramine hydrochloride). Am J Psychiatry. 1958;! 15:459-464.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
6. Walker EA, Katon WJ, Jemelka RP, Roy-Bryne PP. Comorbidity of gastrointestinal complaints, depression, and anxiety in the Epidemiologic Catchment Area (EGA) Study. Am J Med. 1992; 92(1A):26S-30S.
7. Ballard C, Bannister C, Solis M, Oyebode F, Wilcock G. The prevalence, associations and symptoms of depression amongst dementia sufferers. J Affect Disord. 1996;36:135-144.
8. Kokmen E, Beard CM, O'Brien PC, Kurland LT. Epidemiology of dementia in Rochester, Minnesota. Mayo Clin Proc. 1996;71: 275-282.
9. Cassem EH. Depression and anxiety secondary to medical illness. Psychiatr Clin North Am 1990; 13:597-612.
10. Simon GE, VonKorff M, Ustun TB, Gâter R, Gureje O, Sartorius N. Is the lifetime risk of depression actually increasing? J Clin Epidemiol. 1995;48:1109-1118.
11. Klerman GL, Weissman MM. Increasing rates of depression. JAMA. 1989;261 =2229-2235.
12. Klerman GL. Clinical epidemiology of suicide. J Clin Psychiatry. 1987;48(suppl):33-38.
13. Simon GE, VonKorff M. Suicide mortality among patients treated for depression in an insured population. Am J Epidemiol. 1998; 147:155-160.
14. Blair-West GW, Mellsop GW, Eyeson-Annan ML. Down-rating lifetime suicide risk in major depression. Acta Psychiatr Scand. 1997;95:259-263.
15. Chen YW, Dilsaver SC. Lifetime rates of suicide attempts among subjects with bipolar and unipolar disorders relative to subjects with other Axis I disorders. Biol Psychiatry. 1996;39:896-899.
16. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival [published correction appears in JAMA. 1994;271:1082J. JAMA. 1993;270: 1819-1825.
17. Ford DE, Mead LA, Chang PP, Cooper-Patrick L, Wang NY, Klag MJ. Depression is a risk factor for coronary artery disease in men: the precursors study. Arch Intern Med. 1998;158:14221426.
18. Kimmel PL, Peterson RA, Weihs KL, et al. Multiple measurements of depression predict mortality in a longitudinal study of chronic hemodialysis outpatients. Kidney Int. 2000;57:2093-2098.
19. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry. 1993;54: 405-418.
20. Henk HJ, Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW. Medical costs attributed to depression among patients with a history of high medical expenses in a health maintenance organization. Arch Gen Psychiatry. 1996;53:899-904.
21. Regier DA, Hirschfeld RM, Goodwin FK, Burke JD, Lazar JB, Judd LL. The NIMH Depression Awareness, Recognition, and Treatment Program: structure, aims, and scientific basis. Am J Psychiatry. 1988;145:1351-1357.
22. Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity, and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry. 1992;49:809-816.
23. Steffens DC, Krishnan KR, Helms MJ. Are SSRIs better than TCAs? comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety. 1997;6:10-18.
24. Abrams R. Electro-convulsive Therapy. 3rd ed. New York, NY: Oxford University Press; 1997.
25. Thase ME, Greenhouse JB, Frank E, et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry. 1997;54:1009-1015.
26. Reynolds CF, Frank E, Perel JM, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA. 1999;281:39-45.
27. Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000;342:1462-1470.
28. Peretti S, Judge R, Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl. 2000;403:17-25.
29. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord. 2000;58:19-36.
30. Jefferson JW. Just what is a heterocyclic antidepressant? [letterJ. J Clin Psychiatry. 1995;56:433.
31. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry. 2000; 57:503-509.
32. Richelson E. Pharmacology of antidepressants-characteristics of the ideal drug. Mayo Clin Proc. 1994;69:1069-1081.
33. Montgomery SA. Rapid onset of action of venlafaxine. Int Clin Psychopharmacol. 1995;10(suppl 2):21-27.
34. Nierenberg AA, Kremer C, Reimitz P. Mirtazapine and the onset of antidepressant action: survival function analysis-response [abstractJ. Eur Neuropsychopharmacol. 2000;10(suppl 3):S265.
35. Freemantle N, Anderson IM, Young P. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs: meta-regression analysis. Br J Psychiatry. 2000;177:292302.
36. Kragh-Sorensen P, Overo KF, Petersen OL, Jensen K, Parnas W. The kinetics of citalopram: single and multiple dose studies in man. Acta Pharmacol Toxicol (Copenh). 1981 ;48:53-60.
37. Aronoff GR, Bergstrom RF, Pottratz ST, Sloan RS, Wolen RL, Lemberger L. Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther. 1984;36:138144.
38. Schulz P, Dick P, Blaschke TF, Hollister L. Discrepancies between pharmacokinetic studies of amitriptyline. Clin Pharmacokinet. 1985;10:257-268.
39. Laizure SC, DeVane CL, Stewart JT, Dommisse CS, Lai AA. Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose. Clin Pharmacol Ther. 1985; 38:586-589.
40. Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol. 1992;32:716-724.
41. de Vries MH, Raghoebar M, Mathlener IS, van Harten J. Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. Ther Drug Monit. 1992;14:493-498.
42. DeVane CL. Pharmacokinetics of the selective serotonin reuptake inhibitors. J Clin Psychiatry. 1992;53(suppl): 13-20.
43. Timmer CJ, Sitsen JM, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet. 2000;38:461-474.
44. Bergstrom RF, Beasley CM, Levy NB, Blumenfield M, Lemberger L. The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and risk-benefit profile of fluoxetine. Int Clin Psychopharmacol. 1993;8:261-266.
45. Burke WJ, Hendricks SE, Me Arthur-Miller D, et al. Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: results of a placebo-controlled, randomized clinical trial. J Clin Psychopharmacol. 2000;20:423-427.
46. Rudolph RL, Feiger AD. A double-blind, randomized, placebocontrolled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord. 1999;56:171-181.
47. Sjöqvist F, Alexanderson B, Asberg M, et al. Pharmacokinetics and biological effects of nortriptyline in man. Ada Pharmacol Toxicol (Copenh) 1971;29(suppl 3):255-280.
48. Lundmark J, Reis M, Bengtsson F. Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting. Ther Drug Monit. 2000;22:446-454.
49. Charlier C, Pinto E, Ansseau M, Plomteux G. Relationship between clinical effects, serum drug concentration, and concurrent drug interactions in depressed patients treated with citalopram, fluoxetine, clomipramine, paroxetine or venlafaxine. Hum Psychopharmacol. 2000; 15:453-459.
50. Task Force on the Use of Laboratory Tests in Psychiatry. Tricyclic antidepressants-blood level measurements and clinical outcome: an APA Task Force report. Am J Psychiatry. 1985;142: 155-162.
51. Burke MJ, Preskorn SH. Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice. Clin Pharmacokinet. 1999;37:147-165.
52. Classman AH. Cardiovascular effects of antidepressant drugs: updated. Int Clin Psychopharmacol. 1998;13(suppl 5):S25-S30.
53. Roose SP, Classman AH. Antidepressant choice in the patient with cardiac disease: lessons from the Cardiac Arrhythmia Suppression Trial (CAST) studies. J Clin Psychiatry. 1994;55(suppl A):83-87.
54. Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc. 1997;72:835-847.
55. Br0sen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol. 1993;45:1211-1214.
56. Rasmussen BB, Mäenpää J, Pelkonen O, et al. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol. 1995 ;39:151-159.
57. Delbressine LP, Vos RM. The clinical relevance of preclinical data: mirtazapine, a model compound. J Clin Psychopharmacol. 1997;17(suppl 1):29S-33S.
58. Ball SE, Ahern D, Scatina J, Kao J. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism: comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br J Clin Pharmacol. 1997;43:619-626.
59. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. BrJClin Pharmacol. 1992;34:262-265.
60. Skjelbo E, Br0sen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol. 1992;34:256261.
61. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther. 1993 ;53:401-409.
62. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol. 1996;41:149-156.
63. Verhoeven CHJ, Vos RME, Bogaards JJP. Characterization and inhibition of human cytochrome P-450 enzymes involved in the in vitro metabolism of mirtazapine [abstractJ. Eur Neuropsychopharmacol. 1996;6(suppl 4):63.
64. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation. BrJ Clin Pharmacol. 1996;41:339-343.
65. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol. 1994;38:23-31.
66. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol. 1995;15:125-131.
67. Ring BJ, Binkley SN, Roskos L, Wrighton SA. Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed l'-hydroxy midazolam formation in vitro. J Pharmacol Exp Ther. 1995;275:1131-1135.
68. von Moltke LL, Duan SX, Greenblatt DJ, et al. Venlafaxine and metabolites are very weak inhibitors of human cytochrome P4503A isoforms. Biol Psychiatry. 1997;41:377-380.
69. Hartter S, Wetzel H, Hammes E, Hiemke C. Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psvchopharmacology (Berl). 1993;! 10:302308.
70. Jeppesen U, Loft S, Poulsen HE, Br0sen K. A fluvoxaminecaffeine interaction study. Pharmacogenetics. 1996;6:213-222.
71. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Br0sen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. EurJ Clin Pharmacol. 1996;51:73-78.
72. Alfaro CL, Lam YW, Simpson J, Ereshefsky L. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol. 2000;40:58-66.
73. Greene DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH. Coadministration of nefazodone and benzodiazepines, III: a pharmacokinetic interaction study with alprazolam. J Clin Ps\chopharmacol. 1995;15:399-408.
74. Barbhaiya RH, Shukla UA, Kroboth PD, Greene DS. Coadministration of nefazodone and benzodiazepines, II: a pharmacokinetic interaction study with triazolam. J Clin Psychopharmacol. 1995;15:320-326.
75. Avenoso A, Facciola G, Scordo MG, Spina E. No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteers. Ther Drug Monit. 1999;21:577-579.
76. Briley M, Moret C. Neurobiological mechanisms involved in antidepressant therapies. Clin Neuropharmacol. 1993; 16:387400.
77. Vetulani J, Stawarz RJ, Dingell JV, Sulser F. A possible common mechanism of action of antidepressant treatments: reduction in the sensitivity of the noradrenergic cyclic AMP generating system in the rat limbic forebrain. Naitnvn Schmiedebergs Arch Pharmacol. 1976;293:109-114.
78. Sussman N, Ginsberg D. Effects of psychotropic drugs on weight. Psychialr Ann. 1999;29:580-594.
79. Sulser F. Mode of action of antidepressant drugs. J Clin Psvchiatry. 1983;44(5, pt 2): 14-20.
80. Hjorth S, Bengtsson HJ, Kullberg A, Carlzon D, Peilot H, Auerbach SB. Serotonin autoreceptor function and antidepressant drug action. J Psychopharmacol. 2000; 14:177-185.
81. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM. Neurochemical and autonomie pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988;27:399-408.
82. Haddjeri N, Blier P, de Montigny C. Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. J Pharmacol Exp Ther. 1996;277:861871.
83. Tarsy D, Baldessarini RJ. The pathophysiologic basis of tardive dyskinesia. Biol Psychiatry. 1977:12:431-450.
84. Thome J, Sakai N, Shin K-H, et al. cAMP response elementmediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci. 2000:20:4030-4036.
85. Schildkraut JJ. Psychopharmacology of biogenic amines in depressions. Psychopharmacol Bull. 1975;! 1:58-59.
86. Asnis GM, Wetzler S, Sanderson WC, Kahn RS, Van Praag HM. Functional interrelationship of serotonin and norepinephrine: cortisol response to MCPP and DMI in patients with panic disorder, patients with depression, and normal control subjects. Psychiatry Res. 1992;43:65-76.
87. Pickel VM, Joh TH, Reis DJ. A serotonergic innervation of noradrenergic neurons in nucleus locus coeruleus: demonstration by immunocytochemical localization of the transmitter specific enzymes tyrosine and tryptophan hydroxylase. Brain Res. 1977; 131:197-214.
88. Baraban JM, Aghajanian GK. Noradrenergic innervation of serotonergic neurons in the dorsal raphe: demonstration by electron microscopic autoradiography. Brain Res. 1981 ;204:1-11.
89. BeckSickinger AG. Structural characterization and binding sites of G-protein-coupled receptors. Drug Discov Today. 1996; 1:502513.
90. Kalsner S. The question of feedback at the somadendritic region and antidepressant drug action. Brain Res Bull. 2000;52:467473.
91. Artigas F. Pindolol, 5-hydroxytryptamine, and antidepressant augmentation [letterJ. Arch Gen Psychiatry. 1995;52:969-971.
92. Artigas F, Romero L, de Montigny C, Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5HT1A antagonists. Trends Neurosci. 1996;19:378-383.
93. Berman RM, Anand A, Cappiello A, et al. The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. Biol Psychiatry. 1999;45:1170-1177.
94. Rabiner EA, Gunn RN, Castro ME, et al. Beta-blocker binding to human 5-HT(lA) receptors in vivo and in vitro: implications for antidepressant therapy. Neuropsychopharmacology. 2000;23: 285-293.
95. Sargent PA, Kjaer KH, Bench CJ, et al. Brain serotonin 1A receptor binding measured by positron emission tomography with [11CJWAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry. 2000;57:174-180.
96. Drevets WC, Frank E, Price JC, Kupfer DJ, Greer PJ, Mathis C. Serotonin type-1A receptor imaging in depression. Nucl Med Biol. 2000;27:499-507.
97. Peroutka SJ, Snyder SH. Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science. 1980;210:88-90.
98. Meyer JH, Kapur S, Houle S, et al. Prefrontal cortex 5-HT2 receptors in depression: an [18F]setoperone PET imaging study. Am J Psychiatry. 1999;156:1029-1034.
99. Meltzer CC, Price JC, Mathis ÇA, et al. PET imaging of serotonin type 2A receptors in late-life neuropsychiatrie disorders. Am J Psychiatry. 1999; 156:1871-1878.
100. Attar-Lévy D, Martinet J-L, Blin J, et al. The cortical serotonin2 receptors studied with positron-emission tomography and [I8F]setoperone during depressive illness and antidepressant treatment with clomipramine. Biol Psychiatry. 1999;45:180-186.
101. Biver F, Wikler D, Lotstra F, Damhaut P, Goldman S, Mendlewicz J. Serotonin 5-HT2 receptor imaging in major depression: focal changes in orbito-insular cortex. Br J Psychiatry. 1997; 171 : 444-448.
102. Yatham LN, Liddle PF, Shiah IS, et al. Brain serotonin2 receptors in major depression: a positron emission tomography study. Arch Gen Psychiatry. 2000;57:850-858.
103. Yatham LN, Liddle PF, Dennie J, et al. Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: a positron emission tomography study with fluorine-18-labeled setoperone. Arch Gen Psychiatry. 1999; 56:705-711.
104. Massou JM, Trichard C, Attar-Lévy D, et al. Frontal 5-HT2A receptors studied in depressive patients during chronic treatment by selective serotonin reuptake inhibitors. Psychopharmacology (Berl). 1997; 133:99-101.
105. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997;340:249-258.
106. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995;56: 395-401.
107. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 1993;52:1023-1029.
108. Richelson E, Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J PharmacolExpTher. 1984;230:94-102.
109. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994;! 14:559-565.
110. Schwartz J-C, Arrang J-M, Garbarg M, Traiffort E. Histamine. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:397405.
111. Arrang JM, Devaux B, Chodkiewicz JP, Schwartz JC. H3-receptors control histamine release in human brain. / Neurochem. 1988;51:105-108.
112. Schlicker E, Fink K, Hinterthaner M, Gothert M. Inhibition of noradrenaline release in the rat brain cortex via presynaptic H3 receptors. Naunyn Schmiedebergs Arch Pharmacol. 1989;340: 633-638.
113. Arrang JM, Drutel G, Schwartz JC. Characterization of histamine H3 receptors regulating acetylcholine release in rat entorhinal cortex. Br J Pharmacol. 1995;! 14:1518-1522.
114. Drake LA, Fallen JD, Sober A, Doxepin Study Group. Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. J Am Acad Dermatol. 1994;31:613-616.
115. Vo MY, Williamsen AR, Wasserman GS. Toxic reaction from topically applied doxepin in a child with eczema [letterJ. Arch Dermatol. 1995;131:1467-1468.
116. Drake LA, Cohen L, Gillies R, et al. Pharmacokinetics of doxepin in subjects with pruritic atopic dermatitis. J Am Acad Dermatol. 1999;41(2,ptl):209-214.
117. Richelson E. Cholinergic transduction. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:125-134.
118. Janowsky DS, Overstreet DH, Nürnberger JI. Is cholinergic sensitivity a genetic marker for the affective disorders? Am J Med Genet. 1994;54:335-344.
119. Stanton T, Bolden-Watson C, Cusack B, Richelson E. Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics. Biochem Pharmacol. 1993;45:2352-2354.
120. Wander TJ, Nelson A, Okazaki H, Richelson E. Antagonism by antidepressants of serotonin S and S receptors of normal human brain in vitro. Eur J Pharmacol. 1986; 132:115-121.
121. Preskorn SH. A message from Titanic. J Pract Psychiatry Behav Health. 1998;4:236-242.
122. Evans L, Kenardy J, Schneider P, Hoey H. Effect of a selective serotonin uptake inhibitor in agoraphobia with panic attacks: a double-blind comparison of zimeldine, imipramine and placebo. Acta Psychiatr Scand. 1986;73:49-53.
123. Murphy DL, Zohar J, Benkelfat C, Pato MT, Pigott TA, Insel TR. Obsessive-compulsive disorder as a 5-HT subsystem-related behavioural disorder. Br J Psychiatry. 1989;155(suppl 8): 1524.
124. Nutt DJ, Forshall S, Bell C, et al. Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. Eur Neuropsychopharmacol. 1999;9(suppl 3): S81-S86.
125. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol. 1999; 19:6785.
126. Aizenberg D, Zemishlany Z, Weizman A. Cyproheptadine treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clin Neuropharmacol. 1995;18:320-324.
127. Gillman PK. Serotonin syndrome: history and risk. Fundam Clin Pharmacol. 1998; 12:482-491.
128. Steiner W, Fontaine R. Toxic reaction following the combined administration of fluoxetine and L-tryptophan: five case reports. Biol Psychiatry. 1986;21:1067-1071.
129. Bouchard RH, Fourcher E, Vincent P. Fluoxetine and extrapyramidal side effects [letterJ. Am J Psychiatry. 1989;146:13521353.
130. Lambert MT, Trutia C, Petty F. Extrapyramidal adverse effects associated with sertraline. Prog Neuropsychopharmacol Biol Psychiatry. 1998;22:741-748.
131. Poyurovsky M, Meerovich I, Weizman A. Beneficial effect of low-dose mianserin on fluvoxamine-induced akathisia in an obsessive-compulsive patient. Int Clin Psvchopharmacol. 1995; 10: 111-114.
132. Di Rocco A, Brannan T, Prikhojan A, Yahr MD. Sertraline induced parkinsonism: a case report and an in-vivo study of the effect of sertraline on dopamine metabolism. J Neural Transm. 1998;105:247-251.
133. Mandalos GE, Szarek BL. Dose-related paranoid reaction associated with fluoxetine. J Nerv Ment Dis. 1990; 178:57-58.
134. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry. 1990;147:207-210.
135. Wirshing WC, Van Putten T, Rosenberg J, Marder S, Ames D, Hicks-Gray T. Fluoxetine, akathisia, and suicidality: is there a causal connection? [letterJ. Arch Gen Psychiatry. 1992;49:580581.
136. Hamilton MS, Opler LA. Akathisia, suicidality, and fluoxetine. J Clin Psychiatry. 1992;53:401-406.
137. Baldessarini RJ, Marsh ER, Kula NS. Interactions of fluoxetine with metabolism of dopamine and serotonin in rat brain regions. Brain Res. 1992;579:152-156.
138. Ichikawa J, Meltzer HY. Effect of antidepressants on striatal and accumbens extracellular dopamine levels. Eur J Pharmacol. 1995;281:255-261.
139. Richard IH, Maughn A, Kurlan R. Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? a retrospective case series. Mov Disord. 1999; 14:155-157.
140. Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani CB, Pezzoli G. Tolerability of paroxetine in Parkinson's disease: a prospective study. Mov Disord. 2000; 15:986-989.
141. Richard IH, Kurlan R, Tanner C, et al, Parkinson Study Group. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology. 1997:48:10701077.
142. Golden RN, James SP, Sherer MA, Rudorfer MV, Sack DA, Potter WZ. Psychoses associated with bupropion treatment. Am J Psychiatry. 1985; 142:1459-1462.
143. Popli AP, Fuller MA, Jaskiw GE. Sertraline and psychotic symptoms: a case series. A Clin Psychiatry. 1997;9:15-17.
144. Steele TE. Adverse reactions suggesting amoxapine-induced dopamine blockade. Am J Psychiatry. 1982; 139:1500-1501.
145. Robertson AG, Berry R, Meltzer HY. Prolactin stimulating effects of amoxapine and loxapine in psychiatric patients. Psychopharmacology (Berl). 1982;78:287-292.
146. Kapur S, Cho R, Jones C, McKay G, Zipursky RB. Is amoxapine an atypical antipsychotic? positron-emission tomography investigation of its dopamine(2) and serotonin(2) occupancy. Biol Psychiatry. 1999;45:1217-1220.
147. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry. 1999;60:358-363.
148. Boyer WF, Blumhardt CL. The safety profile of paroxetine. J Clin Psychiatry. 1992;53(suppl):61-66.
149. Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. J R Soc Med. 2000;93:457-462.
150. Baxter G, Kennett G, Blaney F, Blackburn T. 5-HT2 receptor subtypes: a family re-united? Trends Pharmacol Sci. 1995; 16: 105-110.
151. Graeff FG, Guimaraes FS, De Andrade TG, Deakin JF. Role of 5HT in stress, anxiety, and depression. Pharmacol Biochem Behav. 1996;54:129-141.
152. Sharpley AL, Elliott JM, Attenburrow MJ, Cowen PJ. Slow wave sleep in humans: role of 5-HT2A and 5-HT2C receptors. Neuropharmacology. 1994;33:467-471.
153. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin, pK. values. J Pharmacol Exp Ther. 1989;251:238246.
154. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68:29-39.
155. Aubry JM, Simon AE, Bertschy G. Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases. J Clin Psychiatry. 2000;61:649-655.
156. Stoll AL, Haura G. Tranylcypromine plus risperidone for treatment-refractory major depression [letterJ. J Clin Psvchopharmacol. 2000;20:495-496.
157. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001:158:131-134.
158. Koutouvidis N, Pratikakis M, Fotiadou A. The use of mirtazapine in a group of 11 patients following poor compliance to selective serotonin reuptake inhibitor treatment due to sexual dysfunction. Int Clin Psychopharmacol. 1999; 14:253-255.
159. Gelenberg AJ, Laukes C, McGahuey C, et al. Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psvchiatry. 2000:61:356-360.
160. Wong DT, Bymaster FP, Mayle DA, Reid LR, Krushinski JH, Robertson DW. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology. 1993;8:23-33.
161. Carlier PR, Lo MM, Lo PC, et al. Synthesis of a potent widespectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group. Bioorg Med Chemien. 1998;8:487-492.
162. Heiser JF, Wilcox CS. Serotonin 5-HT1A receptor agonists as antidepressants: pharmacological rationale and evidence for efficacy. CNS Drugs. 1998:10:343-353.
163. Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 1998;281:1640-1645.
164. Mansbach RS, Brooks EN, Chen YL. Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist. Eur J Pharmacol. 1997;323:21-26.
165. Enserink M. Can the placebo be the cure? Science. 1999;284:238240.
166. Heils A, Teufel A, Pétri S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem. 1996;66: 2621-2624.
167. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274:1527-1531.
168. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalane M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry. 1998:3:508-511.
169. Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene [letterJ. J Clin Psychopharmacol. 2000:20:105-107.
170. Kim DK, Lim SW, Lee S, et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport. 2000;! 1: 215-219.